Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 5-ethyl-2-(5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4h-pyrrolo(3,2-d)pyrimidin-4-one
1. 862189-95-5
2. Mirodenafil [inn]
3. Sk3530
4. Sk-3530
5. Sk3530 Free Base
6. Sk-3530 Free Base
7. Mvix
8. 504g362h0h
9. 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-propyl-1h-pyrrolo[3,2-d]pyrimidin-4-one
10. 5-ethyl-2-[5-[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl-2-propoxyphenyl]-7-propyl-3h-pyrrolo[3,2-d]pyrimidin-4-one
11. Mirodenafilo
12. Mirodenafilum
13. Unii-504g362h0h
14. 5-ethyl-2-(5-((4-(2-hydroxyethyl)piperazin-1-yl)sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4h-pyrrolo(3,2-d)pyrimidin-4-one
15. 5-ethyl-2-(5-{[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl}-2-propoxyphenyl)-7-propyl-3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
16. 862189-96-6
17. Mirodenafil [inci]
18. Mirodenafil [who-dd]
19. Schembl3845775
20. Chembl4297518
21. Schembl15481149
22. Gtpl11738
23. Dtxsid50881265
24. Chebi:136049
25. Bcp07740
26. Ex-a5487
27. Sk3530sk3530
28. Zinc35077050
29. Db11792
30. Ncgc00378703-02
31. Hy-14930
32. Ft-0672413
33. Ft-0699556
34. 189m955
35. A914996
36. Q6873840
37. 5-ethyl-2-(5-(4-(2-hydroxyethyl)piperazine-1-sulfonyl)-2-propoxyphenyl)-7-propyl-3,5-dihydro-4h-pyrrolo(3,2-d)pyrimidin-4-one
38. 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazin-1-ylsulfonyl]-2-n-propoxyphenyl}-7-n-propyl-3,5-dihydro-4h-pyrrolo[3,2-d]pyrimidin-4-one
| Molecular Weight | 531.7 g/mol |
|---|---|
| Molecular Formula | C26H37N5O5S |
| XLogP3 | 2.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 11 |
| Exact Mass | 531.25154047 g/mol |
| Monoisotopic Mass | 531.25154047 g/mol |
| Topological Polar Surface Area | 125 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 902 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Phosphodiesterase 5 Inhibitors
Compounds that specifically inhibit PHOSPHODIESTERASE 5. (See all compounds classified as Phosphodiesterase 5 Inhibitors.)
ABOUT THIS PAGE
A Mirodenafil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mirodenafil, including repackagers and relabelers. The FDA regulates Mirodenafil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mirodenafil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Mirodenafil supplier is an individual or a company that provides Mirodenafil active pharmaceutical ingredient (API) or Mirodenafil finished formulations upon request. The Mirodenafil suppliers may include Mirodenafil API manufacturers, exporters, distributors and traders.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Mirodenafil Drug Master File in Korea (Mirodenafil KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Mirodenafil. The MFDS reviews the Mirodenafil KDMF as part of the drug registration process and uses the information provided in the Mirodenafil KDMF to evaluate the safety and efficacy of the drug.
After submitting a Mirodenafil KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Mirodenafil API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Mirodenafil suppliers with KDMF on PharmaCompass.
Mirodenafil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mirodenafil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mirodenafil GMP manufacturer or Mirodenafil GMP API supplier for your needs.
A Mirodenafil CoA (Certificate of Analysis) is a formal document that attests to Mirodenafil's compliance with Mirodenafil specifications and serves as a tool for batch-level quality control.
Mirodenafil CoA mostly includes findings from lab analyses of a specific batch. For each Mirodenafil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mirodenafil may be tested according to a variety of international standards, such as European Pharmacopoeia (Mirodenafil EP), Mirodenafil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mirodenafil USP).
LOOKING FOR A SUPPLIER?
